Loading…
Bacillus coagulans SANK 70258 suppresses Enterobacteriaceae in the microbiota of ulcerative colitis in vitro and enhances butyrogenesis in healthy microbiota
The aim of this study was to clarify the effect of the spore-forming and lactic acid-producing probiotic strain, Bacillus coagulans SANK 70258, on human colonic microbiota of healthy subjects and ulcerative colitis patients. A model culture system was employed to construct the in vitro human colonic...
Saved in:
Published in: | Applied microbiology and biotechnology 2020-05, Vol.104 (9), p.3859-3867 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The aim of this study was to clarify the effect of the spore-forming and lactic acid-producing probiotic strain,
Bacillus coagulans
SANK 70258, on human colonic microbiota of healthy subjects and ulcerative colitis patients. A model culture system was employed to construct the in vitro human colonic microbiota, to retain the bacterial species richness and simulate the patient’s disordered composition, from the fecal inoculum. Bacterial 16S rRNA gene sequencing confirmed that administration of
B. coagulans
SANK 70258 (at an initial concentration of 4 × 10
7
-total cells/mL) suppressed bacteria related to the family
Enterobacteriaceae
in the microbiota models for both healthy subjects (
P
= 0.016) and ulcerative colitis patients (
P
= 0.023). In addition, administration of
B. coagulans
SANK 70258 increased bacteria related to the family
Lachnospiraceae
(
P
= 0.031), thereby enhancing butyrate production (
P
= 0.031) in the microbiota models of healthy subjects. However, these changes were not observed in the microbiota models of ulcerative colitis patients, likely owing to the low abundance of
Lachnospiraceae
species. This study demonstrates the potential of
B. coagulans
SANK 70258 to exhibit antimicrobial activity against harmful organisms in patients with ulcerative colitis, while improving the intestinal microenvironment by increasing butyrogenesis in healthy persons.
Key Points
•
B. coagulans SANK 70258 treatment reduced colonic Enterobacteriaceae species.
•
B. coagulans SANK 70258 treatment enhanced butyrogenesis in healthy individuals.
•
B. coagulans SANK 70258 treatment increased Lachnospiraceae in healthy persons.
•
B. coagulans SANK 70258 improves the colonic microenvironment in ulcerative colitis. |
---|---|
ISSN: | 0175-7598 1432-0614 |
DOI: | 10.1007/s00253-020-10506-1 |